This is the company's first-ever Say on Pay vote, so there is no prior-year result to consider. The CEO's total pay of approximately $13.5 million is within a reasonable range for a CEO of a $1.8 billion genomics company that grew revenue 41% and turned profitable in 2025, and the pay mix is strongly performance-oriented — the proxy states 93% of CEO compensation is variable or at-risk, with half of equity in performance stock awards that paid out at 200% of target after the company dramatically exceeded its revenue and profitability goals. The company has a meaningful clawback policy, stock ownership guidelines, an independent compensation consultant, and the incentive structure has real, pre-established financial targets with measurable outcomes, all of which support a FOR vote.

The fees paid to Ernst & Young for non-audit work (audit-related fees of $189,250) represent only about 6.7% of core audit fees ($2,810,000), well below the 50% threshold that would raise independence concerns; EY is a Big 4 firm appropriate for a $1.8B company; tenure is not explicitly disclosed in the proxy so the tenure trigger cannot fire per policy; and no material financial restatements are identified.